Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
1 FDA-approved treatment is available for rickettsialpox, including MINOCYCLINE HYDROCHLORIDE (MINOCIN, approved 1972).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
MINOCIN | MINOCYCLINE HYDROCHLORIDE | — | 1972 | Available |
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for rickettsialpox.
4 publications have been identified in PubMed for rickettsialpox. Kisho has analyzed 3 by research type. Research spans Review / Meta-Analysis (33%), Case Report / Case Series (33%), and Epidemiology / Natural History (33%).
Akram SM (2026). [PMID: 28846279](https://pubmed.ncbi.nlm.nih.gov/28846279/). *Unknown Journal*. [Review / Meta-Analysis]
Bartilotti Matos F (2025). [PMID: 40666586](https://pubmed.ncbi.nlm.nih.gov/40666586/). *Cureus*. [Case Report / Case Series]
Kotzyba J (2025). [PMID: 41137175](https://pubmed.ncbi.nlm.nih.gov/41137175/). *Parasites & vectors*. [Epidemiology / Natural History]
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 12:48 AM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
View trials for rickettsialpox